Skip to main content

Pathophysiology

Pathophysiology

Rituximab and rheumatology practice in the COVID-19 era

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

Anifrolumab for the treatment of lupus

Anifrolumab for the treatment of SLE

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

New additions to the Adis Journal Club

Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

JAK inhibitor safety

Data summary, expert discussion, & research news on the potential risks associated with JAK inhibitors.

ACR Convergence 2021 highlights

ACR Convergence 2021

3–9 November: Keep up with the latest news and interviews from the conference.

Febuxostat and cardiovascular risk in people with gout

Febuxostat and cardiovascular risk in people with gout

How will the FAST trial results impact regulatory guidance & clinical practice?

Telemedicine in rheumatology

Telemedicine in rheumatology: COVID-19 and beyond

Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.

Get ready for ACR Convergence 2020

ACR Convergence 2020

5 – 9 November: Preview the conference with session recommendations and updates on upcoming coverage.

Calcium crystal deposition diseases: Beyond gout

Calcium crystal deposition diseases: Beyond gout

In this review, the main clinical manifestations of calcium pyrophosphate dihydrate and basic calcium phosphate crystal deposition are discussed, along with the biological effects of these crystals, current therapeutic approaches and future directions in therapy [read more].
McCarthy GM, Dunne A. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0078-5

06-09-2018 | Calcium crystal deposition disease | Review | Article

Calcium crystal deposition diseases: Beyond gout

McCarthy GM, Dunne A. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0078-5

04-07-2018 | Osteoarthritis | Article

Early morphologic changes in trapeziometacarpal joint bones with osteoarthritis

Schneider MTY et al. Osteoarthritis Cartilage 2018. doi: 10.1016/j.joca.2018.06.008

13-06-2018 | Osteoarthritis | Review | Article

Molecular transport in articular cartilage: What have we learned from the past 50 years?

DiDomenico CD, Lintz M, Bonassar LJ. Nat Rev Rheumatol 2018; 14: 393–403. doi: 10.1038/s41584-018-0033-5

08-06-2018 | Osteoarthritis | Article

The role of thigh muscle and adipose tissue in knee osteoarthritis progression in women: Data from the Osteoarthritis Initiative

Kemnitz J et al. Osteoarthritis Cartilage 2018. doi: 10.1016/j.joca.2018.05.020

08-06-2018 | Pain | Review | Article

Cannabinoids for the treatment of rheumatic diseases: Where do we stand?

Katz-Talmor D et al. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0025-5

04-06-2018 | Inflammation | Review | Article

Novel insights into the role of inflammasomes in autoimmune and metabolic rheumatic diseases

Deuteraiou K et al. Rheumatol Int 2018. doi: 10.1007/s00296-018-4074-5

15-05-2018 | Osteoarthritis | Review | Article

Defining the osteoarthritis patient: Back to the future

Dobson GP et al. Osteoarthritis Cartilage 2018. doi: 10.1016/j.joca.2018.04.018

11-05-2018 | Osteoarthritis | Review | Article

The role of radiography and MRI for eligibility assessment in DMOAD trials of knee OA

Roemer FW et al. Nat Rev Rheumatol 2018; 14: 372–380. doi: 10.1038/s41584-018-0010-z